News
Odonate Therapeutics announces discontinuation of development of Tesetaxel
Following feedback from the FDA in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company .
The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies.
Condition: Breast Cancer HER2-
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins